In severe infective patients who survive the initial inflammatory storm, the immune response often evolves toward a state of immunosuppression, which contributes to increased mortality and severe secondary hospital-acquired infections. However, the role of IL-6 and its receptor antagonists in patients with severe sepsis and septic shock is discussed controversially. To date, the efficacy and safety of IL-6 and its receptor antagonists in children with severe infection is not fully evaluated.
The investigators intend to enroll all children who were hospitalized in pediatric intensive care unit of Children's Hospital of Fudan University from January 2022 to December 2023. Children with a PICU length of day less than 48h will be excluded. Patients who met the inclusion criteria will be divided into trial group and control group. Clinical and demographic data, as well as treatment outcome will be collected from the electronic health record.
Study Type
OBSERVATIONAL
survival rate
The survival rate of children in 28 days after their discharged from PICU
Time frame: within 28 days after they discharged from PICU
length of stay in PICU
Time from PICU admission to discharge
Time frame: up to 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.